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with radiation and TMZ. We also confirmed the 
radiosensitizing effect of Cpd188 of GBL28 cell which was 
originated from a patient with high level of STAT3 expression 
and unmethylated MGMT. 
 
Conclusion: Targeting STAT3 using Cpd188 could be a viable 
therapeutic approach to improve the outcome of current 
standard therapy for glioblastoma patients having high p-
STAT3 expression regardless of MGMT methylation status. 
Work supported by the grant (#2013R1A1A2074531) from the 
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Purpose or Objective: Purpose: Stress responses in cancer 
cells are exaggerated over that of normal tissues include 
signal transduction pathways such as GRP78, PKC, PLC, Rho 
and others. Many of these regulators of cell viability 
translocate of the cell membrane during the stress response. 
Mechanisms of protein transport include motor and scaffold 
proteins such as Tax Interacting protein-1 (TIP-1), which 
translocates to the surface of the cell membrane of cancer 
cells following exposure to ionizing radiation. TIP1 is a 
scaffold protein that moves proteins to and from the cell 
membrane. It is over expressed in poor prognosis cancers.  
 
Material and Methods: Methods: We studied radiation 
induction of TIP1 by western immunoblot and flow 
cytometry. We used siRNA to knock down TIP1 in human GBM 
and NSCLC cell lines. We utilized Anti-TIP1 antibodies 
administered IV to mouse models of human cancer 
xenografts. We measured tumor growth delay. To assess the 
ability of mouse NK cells to target and kill anti-TIP1 antibody-
opsonized lung cancers, we cultured H460, or LLC cells in 96-
well plates at 37oC. After 40 hr., cells were irradiated with 3 
Gy (or shield) to induce TIP1 expression. Cells were 
continued in culture for 4 hr. 10 ug/ml 2C6F3, NMIgG, or 
media were added and incubated for an additional 2 hr. 
Murine NK cells were added and Incubated for 16 hr. 
Cytotoxicity was then determined by cancer cells cytolysis. 
anti-TIP1 antibodies (Ab) that bind to the PDZ domain of this 
protein were administered IV to mice bearing irradiated 
human cancers. 
 
Results: Results: Membrane protein western blots showed a 
significant increase in the expression of TIP-1 protein at 4 
and 24 hrs following irradiation with 3 Gy as compared to 0 
Gy untreated control tumors. Significant levels of the TIP-1 
membrane protein were also present in the irradiated 
tumors, but not in untreated controls, as demonstrated by 
immunohistochemistry. Near-infrared imaging studies showed 
significant targeting and binding of anti-TIP-1 Ab to 
irradiated tumors compared to untreated tumors and IgG 
controls at 72 hrs. Knockdown of TIP1 and blocking Abs that 
bind to the PDZ domain of TIP1 enhance cytotoxicity in 
cancer but not normal tissues. Anti-PDZ-domain Abs 
significantly enhanced cytotoxicity in D54, H1299, H460 and 
A549 human cancer cells. We studied the mechanisms by 
which the Abs enhance cytotoxity and improve tumor control. 
Abs activate caspases 2, 3/7 in irradiated cancers. Moreover, 
Anti-TIP1 antibodies bound to the surface of cancer cells 
activated immune effector cells. In mouse models of human 
cancers, Anti- TIP1 Abs enhanced tumor growth delay after 
radiotherapy when administered IV to mouse models of 
human cancer. 
 
Conclusion: Conclusion: Anti- TIP1 antibodies activate 
immune effector cells and enhance the efficacy of 
radiotherapy specifically in cancer without enhancing the 
response in normal tissues. TIP1 is a molecular target for the 
development of novel radiation sensitizing agents. 
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Purpose or Objective: YB-1, a protein increasingly 
associated with tumour progression and treatment resistance 
in prostate cancer, is the only known ligand of the Notch-3 
receptor. The Notch pathway is an evolutionarily conserved 
signaling system whose inhibition is under scrutiny as a novel 
therapeutic approach. We have previously identified elevated 
Notch-3 mRNA expression in high grade prostate cancer. This 
study investigated the anti-tumour properties of the YB-1 
inhibitor Fisetin, a dietary flavonoid, in an isogenic model of 
radioresistant prostate cancer cells in vitro.  
 
Material and Methods: An isogenic model of radioresistance 
was generated in 22Rv1 prostate cancer cells through 
exposure to 30 x 2-Gy dose fractions. YB-1 and Notch-3 
expression were determined by western blotting in parent, 
aged-matched and radioresistant cells following irradiation 
(5Gy) and/or 60uM Fisetin treatment (24hrs). Patterns of 
expression were related to modification in cell cycle 
distribution through analysis of PI staining by flow cytometry 
and clonogenic survival. The anti-tumour effects of fisetin 
were compared to those of two notch inhibitors DAPT and 
Batimastat.  
 
Results: Following a cumulative total dose of 60Gy, the 
resulting subline RR22Rv1 was associated with a significant 
increase in clonogenic survival (1.3 fold increase in survival 
after 2Gy and 2.2 fold increase after 10Gy) when compared 
to both parent 22Rv1 and aged-matched controls. YB-1 was 
detected in the cytoplasm of all three lines. Expression levels 
were elevated following irradiation (4Gy) in RR22Rv1. 
Radiation (5Gy) inhibited activation and nuclear translocation 
of Notch-3. Fisetin treatment led to a loss of Notch-3 
cytoplasmic expression in RR22Rv1 cells. DAPT and 
Batimastat did not affect clonogenic survival of 22RV1 and 
RR22Rv1 cells. Fisetin induced G2 cell cycle arrest and 
significantly reduced clonogenic survival in untreated and 5-
Gy irradiated parent and RR22Rv1 cells.  
 
Conclusion: This study identifies potential role of the YB-1-
Notch-3 interaction in the radioresistance of prostate cancer 
cells, and highlights fisetin as a novel therapeutic agent for 
the management of prostate cancer.  
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Purpose or Objective: More than 50% all cancer patients 
receive radiation therapy. Despite recent innovations, 
clinical delivery of curative radiation doses is strictly 
restricted by the proximal healthy tissues. Chemical/ 
biological agents to augment the radiosensitization of cancer 
cells are limited by severe off-target toxicity concerns. We 
propose a dual-targeting strategy using tumor vascular-
targeted gold nanoparticles (which amplify 
radiosensitization) combined with the conformal image-
guided radiation therapy to induce tumor vascular disruption. 
This is a unique concept with a clear translational path. 
